263 related articles for article (PubMed ID: 18461061)
1. Strengths and limitations of a systematic review on DMARDs for rheumatoid arthritis.
Smolen JS; Aletaha D
Nat Clin Pract Rheumatol; 2008 Jun; 4(6):296-7. PubMed ID: 18461061
[No Abstract] [Full Text] [Related]
2. New drugs for rheumatoid arthritis.
Kalil AC
N Engl J Med; 2004 Dec; 351(25):2659-61; author reply 2659-61. PubMed ID: 15609422
[No Abstract] [Full Text] [Related]
3. Do all drugs and treatments for rheumatoid arthritis have the same efficacy?
Weisman MH
Nat Clin Pract Rheumatol; 2008 Jun; 4(6):298-9. PubMed ID: 18431369
[No Abstract] [Full Text] [Related]
4. Biologic therapy for early rheumatoid arthritis: the latest evidence.
Castro-Rueda H; Kavanaugh A
Curr Opin Rheumatol; 2008 May; 20(3):314-9. PubMed ID: 18388524
[TBL] [Abstract][Full Text] [Related]
5. [TNF-alpha antagonists in therapy of rheumatoid arthritis].
Gross WL; Gause A
Z Rheumatol; 2003 Jun; 62(3):217. PubMed ID: 12931691
[No Abstract] [Full Text] [Related]
6. New drugs for rheumatoid arthritis.
Roberts LJ
N Engl J Med; 2004 Dec; 351(25):2659-61; author reply 2659-61. PubMed ID: 15602032
[No Abstract] [Full Text] [Related]
7. Severe refractory rheumatoid arthritis successfully treated with combination rituximab and anti-tumor necrosis factor-alpha-blocking agents.
Koumakis E; Wipff J; Avouac J; Kahan A; Allanore Y
J Rheumatol; 2009 Sep; 36(9):2125-6. PubMed ID: 19738227
[No Abstract] [Full Text] [Related]
8. Innovative treatment strategies for patients with rheumatoid arthritis.
van der Kooij SM; Allaart CF; Dijkmans BA; Breedveld FC
Curr Opin Rheumatol; 2008 May; 20(3):287-94. PubMed ID: 18388520
[TBL] [Abstract][Full Text] [Related]
9. Is combination second-line therapy in rheumatoid arthritis more aggressive than helpful?
Berthelot JM; Saraux A; Maugars Y; Prost A; Le Goff P
Rev Rhum Engl Ed; 1999 Apr; 66(4):224-8. PubMed ID: 10339779
[No Abstract] [Full Text] [Related]
10. Anti-tumour necrosis factor {alpha} therapy in patients with rheumatoid arthritis results in a significant and long-lasting decrease of concomitant glucocorticoid treatment.
Naumann L; Huscher D; Detert J; Spengler M; Burmester GR; Buttgereit F
Ann Rheum Dis; 2009 Dec; 68(12):1934-6. PubMed ID: 19910303
[No Abstract] [Full Text] [Related]
11. Are excellent systematic reviews of clinical trials useful for patient care?
Pincus T; Yazici Y; Sokka T
Nat Clin Pract Rheumatol; 2008 Jun; 4(6):294-5. PubMed ID: 18461062
[No Abstract] [Full Text] [Related]
12. [Basic therapeutic and immunosuppressive drugs in rheumatoid arthritis. No fear of "heavy weapons"].
Krüger K
MMW Fortschr Med; 2002 Aug; 144(33-34):25-30. PubMed ID: 12380140
[No Abstract] [Full Text] [Related]
13. Rheumatoid arthritis therapy after tumor necrosis factor and interleukin-1 blockade.
Redlich K; Schett G; Steiner G; Hayer S; Wagner EF; Smolen JS
Arthritis Rheum; 2003 Dec; 48(12):3308-19. PubMed ID: 14673982
[No Abstract] [Full Text] [Related]
14. Novel approaches for the treatment of rheumatoid arthritis: lessons from the evaluation of synovial biomarkers in clinical trials.
Gerlag DM; Tak PP
Best Pract Res Clin Rheumatol; 2008 Apr; 22(2):311-23. PubMed ID: 18455687
[TBL] [Abstract][Full Text] [Related]
15. The evolving use of tumor necrosis factor inhibitors in rheumatoid arthritis.
Kavanaugh A; Cohen S; Cush JJ
J Rheumatol; 2004 Oct; 31(10):1881-4. PubMed ID: 15468347
[No Abstract] [Full Text] [Related]
16. [Current therapeutic strategy for rheumatoid arthritis].
Wollenhaupt J; Alten R; Burkhardt H; Edelmann E; Gromnica-Ihle E; Krause A; Krüger K; Manger B; Lorenz H; Müller-Ladner U; Nüsslein H; Pott HG; Tony H; Schneider M
MMW Fortschr Med; 2006 Oct; 148(42):38-42; quiz 43. PubMed ID: 17621798
[TBL] [Abstract][Full Text] [Related]
17. Systematic monitoring of disease activity using an outcome measure improves outcomes in rheumatoid arthritis.
Katchamart W; Bombardier C
J Rheumatol; 2010 Jul; 37(7):1411-5. PubMed ID: 20436069
[TBL] [Abstract][Full Text] [Related]
18. Escalated conventional therapy for rheumatoid arthritis patients.
Smith MD
Rheumatology (Oxford); 2004 Sep; 43(9):1199; author reply 1199-1200. PubMed ID: 15317963
[No Abstract] [Full Text] [Related]
19. Anti-tumor necrosis factor agents are mostly used in patients with established rheumatoid arthritis compared to early disease -- a reflection of adequate clinical practice.
Haraoui B
J Rheumatol; 2009 Aug; 36(8):1561-2. PubMed ID: 19671804
[No Abstract] [Full Text] [Related]
20. Is there a pharmacoeconomic argument supporting the use of tumor necrosis factor inhibitors in early rheumatoid arthritis?
Kavanaugh A
Nat Clin Pract Rheumatol; 2006 Jul; 2(7):346-7. PubMed ID: 16932716
[No Abstract] [Full Text] [Related]
[Next] [New Search]
